eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2023
vol. 9
 
Share:
Send email
Share:
abstract:
Review paper

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023

Krzysztof Tomasiewicz
1
,
Robert Flisiak
2
,
Jerzy Jaroszewicz
3
,
Piotr Małkowski
4
,
Małgorzata Pawłowska
5
,
Anna Piekarska
6
,
Krzysztof Simon
7
,
Dorota Zarębska-Michaluk
8

  1. Department of Infectious Diseases, Medical University of Lublin, Lublin, Poland
  2. Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland
  3. Department of Infectious Diseases and Hepatology, Medical University of Silesia, Katowice, Poland
  4. Department of General, Transplantation and Liver Surgery, Medical University of Warsaw, Warsaw, Poland
  5. Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland
  6. Department of Infectious Diseases and Hepatology, Medical University of Łódz, Łódź, Poland
  7. Department of Infectious Diseases and Hepatology, Wrocław Medical University, Wrocław, Poland
  8. Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland
Clin Exp HEPATOL 2023; 9, 1: 1-8
DOI: https://doi.org/10.5114/ceh.2023.125957
Online publish date: 2023/03/24
View full text Get citation
 
PlumX metrics:
The recommendations define the principles of diagnosis and treatment of hepatitis C virus (HCV) infection according to the latest knowledge. The main goal of the treatment of HCV infection is to eliminate the virus from the body, which in turn leads to stopping the progression or causes the regression of previously formed changes in the liver. The current version of the guidelines prioritizes pangenotypic regimens and includes guidelines for special patient populations such as children, patients with cirrhosis, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection, patients with renal failure, liver failure and lack of response to previous therapies as well as patients in the peri-transplant period.
keywords:

therapy, liver, HCV, recommendations, viral hepatitis
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.